In Vivo Antibacterial Activity of MRX-I, a New Oxazolidinone | Zendy

Congran Li | Zendy; Qianqian Zhai | Zendy; Xiukun Wang | Zendy; Xinxin Hu | Zendy; Guoqing Li | Zendy; Weixin Zhang | Zendy; Jing Pang | Zendy; Xi Lü | Zendy; Hong Yuan | Zendy; M. F. GORDEEV | Zendy; Letian Chen | Zendy; Xinyi Yang | Zendy; Xuefu You | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vivo Antibacterial Activity of MRX-I, a New Oxazolidinone

Author(s) -

Congran Li,

Qianqian Zhai,

Xiukun Wang,

Xinxin Hu,

Guoqing Li,

Weixin Zhang,

Jing Pang,

Xi Lü,

Hong Yuan,

M. F. GORDEEV,

Letian Chen,

Xinyi Yang,

Xuefu You

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01526-13

Subject(s) - linezolid , microbiology and biotechnology , streptococcus pneumoniae , vancomycin , antibiotics , penicillin , staphylococcus aureus , medicine , antibacterial agent , in vivo , biology , bacteria , genetics

MRX-I is a potent oxazolidinone antibiotic against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), penicillin-intermediate S. pneumoniae (PISP), and vancomycin-resistant enterococci (VRE). In this study, the in vivo efficacy of orally administered MRX-I was evaluated using linezolid as a comparator. MRX-I showed the same or better efficacy than linezolid in both systemic and local infection models against the tested strains.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research